SPDL1 and melanoma: Soluble PD-L1 (sPD-L1) is the circulating form of the PD-L1 protein, which can bind to programmed death (PD-1) receptors and inhibit immune responses, and elevated sPD-L1 levels have been correlated with poor outcomes in melanoma patients treated with ICIs.